← 產業報告目錄

Biosimulation Market by Phase (Drug Discovery, Preclinical, Regulatory), Modality (Antibody, Peptide), Application (Molecular Design, PK/PD, QSP, Trial Simulation, Disease Modeling), Indication (Cardio, Onco), End User (CRO, Pharma) – Global Forecast to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-06-16頁數 413報告編號 HIT3629

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The biosimulation market is projected to reach USD 9.24 billion by 2031 from USD 4.27 billion in 2026, at a CAGR of 16.7% from 2026 to 2031. The growth of the biosimulation market is being driven by the increasing complexity of drug discovery and development, rising pressure to improve R&D productivity, and the growing need to reduce late-stage clinical failures through predictive modeling approaches. Pharmaceutical and biotechnology companies are increasingly utilizing biosimulation technologies to evaluate drug candidates, optimize dosing strategies, predict safety and efficacy outcomes, and support regulatory decision-making before advancing compounds into costly laboratory and clinical studies. Furthermore, regulatory agencies are increasingly recognizing model-informed drug development (MIDD) approaches. In January ‘25, the International Council for Harmonisation (ICH) reached Step 4 adoption of the M15 Guideline on Model-Informed Drug Development, providing a harmonized framework for the application of modeling and simulation in regulatory submissions and drug development programs. In addition, continued growth in pharmaceutical R&D spending and the increasing adoption of artificial intelligence, machine learning, and digital drug development technologies are accelerating demand for advanced biosimulation platforms. However, market growth may be constrained by the high costs associated with software implementation and model development, challenges related to data quality and model validation, limited availability of skilled pharmacometricians and computational scientists, and integration complexities across diverse research environments. “In 2025, the pharmaceutical & biotechnology companies segment accounted for the largest market share, by end user.” By end user, pharmaceutical and biotechnology companies represented the largest share of the biosimulation market in 2025. Their leadership stems from the growing need to improve drug development efficiency, increase the probability of clinical success, and manage increasingly complex therapeutic pipelines. These organizations extensively utilize biosimulation tools to support compound screening, translational research, exposure-response analysis, clinical trial optimization, and regulatory interactions. The rising focus on innovative modalities such as biologics, gene therapies, mRNA-based therapeutics, and precision medicine has further increased reliance on advanced modeling and simulation technologies. Moreover, the need to reduce attrition rates, accelerate time-to-market, and maximize returns on R&D investments has encouraged pharmaceutical and biotechnology companies to incorporate biosimulation across multiple stages of the drug development process, strengthening their position as the largest end-user segment in the market. “The cloud-based models segment by deployment mode is expected to register the fastest growth during the forecast period.” By deployment mode, cloud-based solutions are expected to be the fastest-growing segment in the biosimulation market during the forecast period. This growth is driven by the increasing need for scalable computing resources, collaborative research environments, and cost-effective access to advanced modeling and simulation capabilities. Cloud-based platforms enable pharmaceutical and biotechnology companies to perform computationally intensive tasks such as PBPK modeling, QSP, molecular dynamics, AI-driven drug discovery, and virtual patient simulations without significant investments in on-premises infrastructure. These solutions also facilitate seamless data sharing, global collaboration, and faster model deployment across geographically distributed research teams. Furthermore, the growing integration of artificial intelligence, machine learning, and high-performance computing with cloud environments is accelerating the adoption of cloud-based biosimulation platforms, particularly among small and mid-sized organizations seeking greater flexibility and reduced operational costs. “Asia Pacific is expected to witness the highest growth rate during the forecast period.” The Asia Pacific region is projected to experience the highest growth rate in the biosimulation market over the forecast period. Key factors driving this growth include expanding pharmaceutical and biotechnology R&D activities, increasing adoption of AI-driven drug discovery technologies, rising demand for cost-effective drug development strategies, and growing investments in computational biology and precision medicine. Countries such as China, India, Japan, South Korea, and Singapore are strengthening their life sciences ecosystems through government-backed innovation programs, expanding biopharmaceutical manufacturing capabilities, and the growing use of advanced modeling and simulation tools across research workflows. Furthermore, the increasing presence of global pharmaceutical companies, contract research organizations, and academic research institutes is accelerating the adoption of biosimulation platforms in the region. Recent developments also highlight the region's momentum; in May 2025, Insilico Medicine announced the global expansion of its research and development operations to further advance AI-powered drug discovery and development, reinforcing Asia Pacific's position as a key hub for innovation in computational life sciences and biosimulation. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20% • By Designation - C-level: 35%, Director-level: 25%, and Others: 40% • By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, Latin America: 2% Key Market Players The key players in the biosimulation market include Certara (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Simulations Plus (US), and Advanced Chemistry Development, Inc. (Revvity) (Canada). Research Coverage: This research report categorizes the biosimulation market based on offering (software, services), phase of development (drug discovery, preclinical development, early clinical development, late clinical development, regulatory, commercial & market access), modality (antibody design, peptide discovery, enzyme engineering, bifunctional degraders, TCR modeling, others), application (molecular design & optimization, PK/PD modeling, PBPK modeling, quantitative systems pharmacology (QSP), ADME/toxicity prediction, clinical trial simulation, disease modeling, other applications), therapeutic area (oncology, cardiovascular diseases, neurological disorders, infectious diseases, metabolic & endocrine disorders, other therapeutic areas), deployment mode (on-premises models, cloud-based models, hybrid models), end user (pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, regulatory bodies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions; and recent developments associated with the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report. Reasons to Buy the Report This report will help established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market. This report provides insights on:  Analysis of key drivers (Increasing R&D investments in pharmaceutical and biotechnology industries, Growing adoption of biosimulation software by regulatory bodies, Integration of technologically advanced quantitative systems pharmacology (QSP), Need to curtail drug discovery and development costs), restraints (Lack of standardization, Data availability and quality), opportunities (Expansion into novel therapeutic modalities, Use of biosimulation solutions for pediatric drug development), and challenges (Difficulties in matching complexity of biological systems and processes, Shortage of biosimulation and modeling experts) influencing the growth of the biosimulation market.  Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the biosimulation market.  Market Development: Comprehensive information on the lucrative emerging markets, offerings, phases of development, modalities, applications, therapeutic areas, deployment modes, end users, and regions.  Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the biosimulation market.  Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players, such as Certara (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Simulations Plus (US), Advanced Chemistry Development, Inc. (Revvity) (Canada), in the biosimulation market.
目錄 Table of Contents
1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 MARKET SCOPE 35 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 37 1.4 CURRENCY CONSIDERED 38 1.5 LIMITATIONS 38 1.6 STAKEHOLDERS 39 1.7 SUMMARY OF CHANGES 40 2 EXECUTIVE SUMMARY 41 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 43 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 44 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46 3 PREMIUM INSIGHTS 48 3.1 BIOSIMULATION MARKET OVERVIEW 48 3.2 BIOSIMULATION MARKET, BY OFFERING & REGION 49 3.3 BIOSIMULATION MARKET: GEOGRAPHIC SNAPSHOT 50 4 MARKET OVERVIEW 51 4.1 INTRODUCTION 51 4.2 MARKET DYNAMICS 52 4.2.1 DRIVERS 52 4.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 52 4.2.1.2 Growing adoption of biosimulation software by regulatory bodies 53 4.2.1.3 Integration of technologically advanced quantitative systems pharmacology 54 4.2.1.4 Need to curtail drug discovery and development costs 54 4.2.2 RESTRAINTS 55 4.2.2.1 Lack of standardization 55 4.2.2.2 Data availability and quality 55 4.2.3 OPPORTUNITIES 56 4.2.3.1 Expansion into novel therapeutic modalities 56 4.2.3.2 Use of biosimulation solutions for pediatric drug development 56 4.2.4 CHALLENGES 56 4.2.4.1 Difficulties in matching complexity of biological systems and processes 56 4.2.4.2 Shortage of biosimulation and modeling experts 57 4.3 UNMET NEEDS AND WHITE SPACES 57 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 58 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 58 5 INDUSTRY TRENDS 60 5.1 PORTER’S FIVE FORCES ANALYSIS 60 5.1.1 BARGAINING POWER OF SUPPLIERS 61 5.1.2 BARGAINING POWER OF BUYERS 61 5.1.3 THREAT OF SUBSTITUTES 61 5.1.4 THREAT OF NEW ENTRANTS 61 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 62 5.2 MACROECONOMIC INDICATORS 62 5.2.1 INTRODUCTION 62 5.2.2 GDP TRENDS AND FORECAST 62 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 62 5.3 VALUE CHAIN ANALYSIS 63 5.3.1 RESEARCH & PRODUCT DEVELOPMENT 64 5.3.2 DATA INPUTS & COMPUTATIONAL INFRASTRUCTURE 64 5.3.3 PLATFORM DEVELOPMENT AND INTEGRATION 64 5.3.4 DISTRIBUTION 65 5.3.5 MARKETING AND SALES 65 5.3.6 POST-SALES SERVICES 65 5.4 ECOSYSTEM ANALYSIS 65 5.5 PRICING ANALYSIS 67 5.5.1 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY OFFERING (2025) 67 5.5.2 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY REGION (2025) 68 5.6 KEY CONFERENCES AND EVENTS, 2026–2027 68 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69 5.8 INVESTMENT AND FUNDING SCENARIO 70 5.9 CASE STUDY ANALYSIS 71 5.10 IMPACT OF 2025 US TARIFF – BIOSIMULATION MARKET 73 5.10.1 INTRODUCTION 73 5.10.2 KEY TARIFF RATES 74 5.10.3 PRICE IMPACT ANALYSIS 75 5.10.4 IMPACT ON COUNTRY/REGION 75 5.10.4.1 US 75 5.10.4.2 Europe 75 5.10.4.3 Asia Pacific 75 5.10.5 IMPACT ON END-USE INDUSTRIES 76 5.10.5.1 Pharmaceutical and Biotechnology Companies 76 5.10.5.2 Contract Research Organizations 76 5.10.5.3 Academic & Research Institutes 76 5.10.5.4 Regulatory Bodies 76 5.10.5.5 Other End Users 76 6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION 77 6.1 KEY EMERGING TECHNOLOGIES 77 6.1.1 MATHEMATICAL MODELING 77 6.1.2 POPULATION PK MODELING 77 6.1.3 MOLECULAR MODELING & SIMULATION 78 6.2 COMPLEMENTARY TECHNOLOGIES 78 6.2.1 DATA ANALYTICS 78 6.2.2 ARTIFICIAL INTELLIGENCE 78 6.3 ADJACENT TECHNOLOGIES 79 6.3.1 COMPUTATIONAL CHEMISTRY 79 6.3.2 AI-DRIVEN DRUG DISCOVERY 79 6.4 TECHNOLOGY/PRODUCT ROADMAP 79 6.5 PATENT ANALYSIS 80 6.5.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION MARKET 80 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 81 6.6 FUTURE APPLICATIONS 83 6.6.1 AI-ENABLED INTELLIGENT MODELING AND PREDICTION 84 6.6.2 VIRTUAL CLINICAL TRIALS AND DIGITAL PATIENT COHORTS 84 6.6.3 MULTI-SCALE BIOLOGICAL SYSTEMS SIMULATION 84 6.7 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 84 6.7.1 INTRODUCTION 84 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOSIMULATION MARKET 85 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 86 6.7.3.1 Artificial intelligence in drug discovery and development 86 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 87 6.7.4.1 AI-Driven Drug Discovery Market 87 6.7.4.2 Digital Twin Healthcare Market 87 6.7.4.3 Real-World Evidence (RWE) Market 87 6.7.5 USER READINESS AND IMPACT ASSESSMENT 88 6.7.5.1 User readiness 88 6.7.5.1.1 User A: Pharmaceutical & biotechnology companies 88 6.7.5.1.2 User B: Contract research organizations (CROs) 88   6.7.5.2 Impact assessment 89 6.7.5.2.1 User A: Pharmaceutical & biotechnology companies 89 6.7.5.2.1.1 Implementation 89 6.7.5.2.1.2 Impact 89 6.7.5.2.2 User B: Contract research organizations 89 6.7.5.2.2.1 Implementation 89 6.7.5.2.2.2 Impact 89 7 REGULATORY LANDSCAPE 90 7.1 REGIONAL REGULATIONS AND COMPLIANCE 90 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS 91 7.1.2 REGULATORY FRAMEWORK 94 7.1.2.1 North America 94 7.1.2.2 Europe 94 7.1.2.3 Asia Pacific 95 7.1.2.4 Latin America 95 7.1.2.5 Middle East & Africa 96 7.1.3 INDUSTRY STANDARDS 96 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98 8.1 INTRODUCTION 98 8.2 DECISION-MAKING PROCESS 98 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 98 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 99 8.3.2 BUYING CRITERIA 99 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 100 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 101 8.5.1 UNMET NEEDS 101 8.5.2 END-USER EXPECTATIONS 102 8.6 MARKET PROFITABILITY 103 9 BIOSIMULATION MARKET, BY OFFERING 104 9.1 INTRODUCTION 105 9.2 SOFTWARE 105 9.2.1 AI-ENABLED PLATFORMS AND MODEL-INFORMED DRUG DEVELOPMENT DRIVE MARKET EXPANSION 105 9.3 SERVICES 106 9.3.1 CONSULTING & ADVISORY 108 9.3.1.1 Strategic R&D decision-making and biosimulation integration drive growth in consulting services 108 9.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 109 9.3.2.1 Growing enterprise-wide adoption of biosimulation platforms fuels demand 109 9.3.3 DATA ANALYSIS & INTERPRETATION 110 9.3.3.1 Expanding scientific data volumes and demand for actionable insights drive growth 110 10 BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT 112 10.1 INTRODUCTION 113 10.2 DRUG DISCOVERY 113 10.2.1 AI-DRIVEN MOLECULAR DESIGN AND VIRTUAL SCREENING STRENGTHEN BIOSIMULATION USE IN EARLY RESEARCH 113 10.3 PRECLINICAL DEVELOPMENT 115 10.3.1 GROWING EMPHASIS ON REDUCING ANIMAL TESTING AND IMPROVING TRANSLATIONAL PREDICTABILITY DRIVES BIOSIMULATION ADOPTION 115 10.4 EARLY CLINICAL DEVELOPMENT 116 10.4.1 RISING DEMAND FOR FIRST-IN-HUMAN DOSE OPTIMIZATION AND TRIAL DESIGN EFFICIENCY DRIVES BIOSIMULATION ADOPTION 116 10.5 LATE CLINICAL DEVELOPMENT 117 10.5.1 GROWING NEED FOR TRIAL OPTIMIZATION AND EVIDENCE GENERATION IN LARGE-SCALE STUDIES DRIVES BIOSIMULATION ADOPTION 117 10.6 REGULATORY 118 10.6.1 INCREASING USE OF QUANTITATIVE EVIDENCE IN REGULATORY SUBMISSIONS DRIVES BIOSIMULATION ADOPTION 118 10.7 COMMERCIAL & MARKET ACCESS 119 10.7.1 EXPANDING USE OF HEALTH ECONOMIC MODELING AND REAL-WORLD EVIDENCE ENHANCES MARKET ACCESS STRATEGIES 119 11 BIOSIMULATION MARKET, BY MODALITY 120 11.1 INTRODUCTION 121 11.2 ANTIBODY DESIGN 121 11.2.1 AI-BASED PROTEIN ENGINEERING AND RISING BIOLOGICS PIPELINES ACCELERATE BIOSIMULATION USE IN ANTIBODY DESIGN 121 11.3 PEPTIDE DISCOVERY 122 11.3.1 ADVANCEMENTS IN THERAPEUTIC PEPTIDE ENGINEERING AND AI-DRIVEN SEQUENCE OPTIMIZATION FUEL BIOSIMULATION ADOPTION 122 11.4 ENZYME ENGINEERING 123 11.4.1 INCREASING ADOPTION OF COMPUTATIONAL PROTEIN DESIGN ACCELERATES BIOSIMULATION USE IN ENZYME DEVELOPMENT 123 11.5 BIFUNCTIONAL DEGRADERS 124 11.5.1 RISING INTEREST IN TARGETED PROTEIN DEGRADATION DRIVES BIOSIMULATION ADOPTION 124 11.6 TCR MODELING 125 11.6.1 EXPANDING CELL THERAPY RESEARCH AND PRECISION IMMUNOTHERAPY DEVELOPMENT DRIVE ADOPTION 125 11.7 OTHER MODALITIES 126 11.7.1 ADVANCES IN COMPUTATIONAL DRUG DESIGN AND NEXT-GENERATION NUCLEIC ACID THERAPIES EXPAND APPLICATIONS 126 12 BIOSIMULATION MARKET, BY APPLICATION 128 12.1 INTRODUCTION 129 12.2 MOLECULAR DESIGN & OPTIMIZATION 129 12.2.1 AI-ENABLED MOLECULAR GENERATION AND CLOUD-BASED DESIGN PLATFORMS ACCELERATE LEAD OPTIMIZATION 129 12.3 PK/PD MODELING 130 12.3.1 INCREASING FOCUS ON EXPOSURE-RESPONSE UNDERSTANDING AND PRECISION DOSING EXPANDS PK/PD MODELING ADOPTION 130 12.4 PBPK MODELING 132 12.4.1 GROWING NEED FOR PREDICTIVE HUMAN PHARMACOKINETIC ASSESSMENTS DRIVES ADOPTION OF PBPK MODELING 132 12.5 QUANTITATIVE SYSTEMS PHARMACOLOGY 133 12.5.1 INCREASING FOCUS ON MECHANISTIC DISEASE UNDERSTANDING AND PRECISION THERAPEUTICS DRIVES ADOPTION 133 12.6 ADME/TOXICITY PREDICTION 134 12.6.1 GROWING EMPHASIS ON EARLY SAFETY ASSESSMENT AND CANDIDATE QUALITY IMPROVEMENT DRIVES ADME/TOXICITY MODELING ADOPTION 134 12.7 CLINICAL TRIAL SIMULATION 135 12.7.1 INCREASING CLINICAL TRIAL VOLUMES AND STUDY COMPLEXITY DRIVE ADOPTION OF SIMULATION-BASED DEVELOPMENT STRATEGIES 135 12.8 DISEASE MODELING 136 12.8.1 GROWING FOCUS ON PRECISION MEDICINE AND MECHANISTIC UNDERSTANDING OF COMPLEX DISEASES DRIVES ADOPTION 136 12.9 OTHER APPLICATIONS 137 12.9.1 ADVANCEMENTS IN SYSTEMS-LEVEL BIOLOGICAL ANALYSIS AND FORMULATION OPTIMIZATION EXPAND BIOSIMULATION APPLICATIONS 137 13 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 139 13.1 INTRODUCTION 140 13.2 ONCOLOGY 140 13.2.1 EXPANDING PRECISION ONCOLOGY RESEARCH AND RISING CANCER TRIAL ACTIVITY ACCELERATE BIOSIMULATION ADOPTION 140 13.3 CARDIOVASCULAR DISEASES 141 13.3.1 RISING BURDEN OF CARDIOVASCULAR DISORDERS AND EXPANSION OF LARGE-SCALE OUTCOME TRIALS DRIVE BIOSIMULATION ADOPTION 141 13.4 NEUROLOGICAL DISORDERS 142 13.4.1 HIGH CNS TRIAL FAILURE AND ACCESS BARRIERS STRENGTHEN NEED FOR BIOSIMULATION IN NEUROLOGY DEVELOPMENT 142 13.5 INFECTIOUS DISEASES 143 13.5.1 PERSISTENT GLOBAL DISEASE BURDEN AND OUTBREAK PREPAREDNESS NEEDS DRIVE BIOSIMULATION ADOPTION 143 13.6 METABOLIC & ENDOCRINE DISORDERS 144 13.6.1 RISING DIABETES AND OBESITY BURDEN EXPANDS NEED FOR SIMULATION-DRIVEN METABOLIC DRUG DEVELOPMENT 144   13.7 OTHER THERAPEUTIC AREAS 145 13.7.1 EXPANSION OF RARE DISEASE, IMMUNOLOGY, RESPIRATORY, GASTROINTESTINAL, AND RENAL DRUG DEVELOPMENT BROADENS BIOSIMULATION APPLICATIONS 145 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODE 147 14.1 INTRODUCTION 148 14.2 ON-PREMISES 148 14.2.1 ESTABLISHED INFRASTRUCTURE AND DATA GOVERNANCE REQUIREMENTS SUSTAIN ADOPTION 148 14.3 CLOUD-BASED MODELS 149 14.3.1 SCALABLE COMPUTING INFRASTRUCTURE AND AI-DRIVEN RESEARCH WORKFLOWS ACCELERATE CLOUD ADOPTION 149 14.4 HYBRID MODELS 150 14.4.1 BALANCING SECURITY AND SCALABILITY ENCOURAGES ADOPTION OF HYBRID DEPLOYMENT STRATEGIES 150 15 BIOSIMULATION MARKET, BY END USER 152 15.1 INTRODUCTION 153 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 153 15.2.1 HIGH R&D SPENDING AND EXPANDING DRUG PIPELINES DRIVE BIOSIMULATION ADOPTION AMONG PHARMA & BIOTECH COMPANIES 153 15.3 CONTRACT RESEARCH ORGANIZATIONS 154 15.3.1 GROWING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES EXPANDS BIOSIMULATION ADOPTION AMONG CROS 154 15.4 CONSULTING SERVICE COMPANIES 155 15.4.1 EXPANDING COMPUTATIONAL RESEARCH AND PUBLIC FUNDING INITIATIVES SUPPORT BIOSIMULATION ADOPTION IN ACADEMIA 155 15.5 REGULATORY BODIES 156 15.5.1 GROWING ACCEPTANCE OF MODEL-INFORMED EVIDENCE STRENGTHENS BIOSIMULATION ADOPTION AMONG REGULATORY AGENCIES 156 15.6 OTHER END USERS 157 15.6.1 EXPANDING USE OF COMPUTATIONAL MODELING BEYOND TRADITIONAL DRUG DEVELOPMENT BROADENS BIOSIMULATION ADOPTION 157 16 BIOSIMULATION MARKET, BY REGION 159 16.1 INTRODUCTION 160 16.2 NORTH AMERICA 160 16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 161 16.2.2 US 165 16.2.2.1 Regulatory science and AI-driven innovation accelerate biosimulation adoption 165 16.2.3 CANADA 169 16.2.3.1 Expanding computational drug research strengthens biosimulation adoption 169   16.3 EUROPE 174 16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175 16.3.2 GERMANY 179 16.3.2.1 Strong pharmaceutical research base drives advanced modeling adoption 179 16.3.3 FRANCE 183 16.3.3.1 Biopharma innovation and research commercialization support market expansion 183 16.3.4 UK 187 16.3.4.1 Regulatory innovation and AI drug discovery accelerate adoption 187 16.3.5 ITALY 191 16.3.5.1 Research modernization efforts create opportunities for computational development 191 16.3.6 SPAIN 195 16.3.6.1 Expanding clinical trial leadership creates need for development efficiency 195 16.3.7 REST OF EUROPE 199 16.4 ASIA PACIFIC 204 16.4.1 CLINICAL TRIAL INITIATIONS IN ASIA PACIFIC (2014 AND 2024) 205 16.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 205 16.4.3 CHINA 210 16.4.3.1 AI-driven drug discovery reshapes pharmaceutical development strategies 210 16.4.4 JAPAN 215 16.4.4.1 Demographic pressures and innovation efficiency drive biosimulation adoption 215 16.4.5 INDIA 219 16.4.5.1 Cost-efficient innovation and clinical research expansion support growth 219 16.4.6 AUSTRALIA 223 16.4.6.1 Translational research ecosystem supports advanced development approaches 223 16.4.7 SOUTH KOREA 227 16.4.7.1 Government-led biotechnology ambitions accelerate digital drug development 227 16.4.8 REST OF ASIA PACIFIC 231 16.5 LATIN AMERICA 236 16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 236 16.5.2 BRAZIL 240 16.5.2.1 Leading Regional Clinical Research Activity Drives Modeling Adoption 240 16.5.3 MEXICO 244 16.5.3.1 Nearshoring Trends Strengthen Pharmaceutical Development Capabilities 244 16.5.4 REST OF LATIN AMERICA 248 16.6 MIDDLE EAST & AFRICA 253 16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 253 16.6.2 GCC COUNTRIES 257 16.6.2.1 National biotechnology strategies accelerate computational drug development 257 16.6.3 SAUDI ARABIA 262 16.6.3.1 Vision 2030 investments accelerate biotechnology and research capabilities 262 16.6.4 UAE 266 16.6.4.1 Innovation ecosystems and cross-border collaboration support growth 266 16.6.5 OTHER GCC COUNTRIES 270 16.6.6 SOUTH AFRICA 274 16.6.6.1 Growing clinical research activities and pharmaceutical innovation support biosimulation adoption 274 16.6.7 REST OF MIDDLE EAST & AFRICA 278 17 COMPETITIVE LANDSCAPE 283 17.1 OVERVIEW 283 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 283 17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET 283 17.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 286 17.4 MARKET SHARE ANALYSIS, 2025 286 17.5 BRAND COMPARISON 289 17.6 VALUATION & FINANCIAL METRICS 290 17.6.1 FINANCIAL METRICS 290 17.6.2 COMPANY VALUATION 290 17.7 COMPANY EVALUATION MATRIX, KEY PLAYERS (2025) 291 17.7.1 STARS 291 17.7.2 EMERGING LEADERS 291 17.7.3 PERVASIVE PLAYERS 291 17.7.4 PARTICIPANTS 292 17.8 COMPANY FOOTPRINT: KEY PLAYERS, 2025 293 17.8.1 COMPANY FOOTPRINT 293 17.8.1.1 Region footprint 294 17.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 299 17.9.1 PROGRESSIVE COMPANIES 299 17.9.2 RESPONSIVE COMPANIES 299 17.9.3 DYNAMIC COMPANIES 299 17.9.4 STARTING BLOCKS 299 17.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 301 17.9.5.1 Detailed list of key startups/SMEs 301 17.9.5.2 Competitive benchmarking of startups/SMEs 302 17.10 COMPETITIVE SCENARIO 303 17.10.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 303 17.10.2 DEALS 304 17.10.3 OTHER DEVELOPMENTS 305 18 COMPANY PROFILES 306 18.1 KEY PLAYERS 306 18.1.1 CERTARA 306 18.1.1.1 Business overview 306 18.1.1.2 Products & services offered 308 18.1.1.3 Recent developments 310 18.1.1.3.1 Product launches & enhancements 310 18.1.1.3.2 Deals 313 18.1.1.3.3 Other developments 314 18.1.1.4 MnM view 314 18.1.1.4.1 Right to win 314 18.1.1.4.2 Strategic choices 314 18.1.1.4.3 Weaknesses & competitive threats 315 18.1.2 DASSAULT SYSTÈMES 316 18.1.2.1 Business overview 316 18.1.2.2 Products & services offered 318 18.1.2.3 Recent developments 319 18.1.2.3.1 Product launches & enhancements 319 18.1.2.3.2 Deals 321 18.1.2.3.3 Other developments 322 18.1.2.4 MnM view 322 18.1.2.4.1 Right to win 322 18.1.2.4.2 Strategic choices 322 18.1.2.4.3 Weaknesses & competitive threats 322 18.1.3 SCHRÖDINGER, INC. 323 18.1.3.1 Business overview 323 18.1.3.2 Products & services offered 325 18.1.3.3 Recent developments 326 18.1.3.3.1 Product launches & enhancements 326 18.1.3.3.2 Deals 327 18.1.3.3.3 Other developments 328 18.1.3.4 MnM view 328 18.1.3.4.1 Right to win 328 18.1.3.4.2 Strategic choices 328 18.1.3.4.3 Weaknesses & competitive threats 329   18.1.4 SIMULATIONS PLUS 330 18.1.4.1 Business overview 330 18.1.4.2 Products & services offered 332 18.1.4.3 Recent Developments 335 18.1.4.3.1 Product launches & enhancements 335 18.1.4.3.2 Deals 336 18.1.4.3.3 Other developments 338 18.1.4.4 MnM view 339 18.1.4.4.1 Right to win 339 18.1.4.4.2 Strategic choices 339 18.1.4.4.3 Weaknesses & competitive threats 339 18.1.5 GENEDATA AG (A DANAHER COMPANY) 340 18.1.5.1 Business overview 340 18.1.5.2 Products & services offered 342 18.1.5.3 Recent developments 342 18.1.5.3.1 Product launches & enhancements 342 18.1.5.3.2 Deals 343 18.1.5.4 MnM view 343 18.1.5.4.1 Right to win 343 18.1.5.4.2 Strategic choices 343 18.1.5.4.3 Weaknesses & competitive threats 343 18.1.6 ADVANCED CHEMISTRY DEVELOPMENT, INC. 344 18.1.6.1 Business overview 344 18.1.6.2 Products & Services Offered 345 18.1.6.3 Recent developments 345 18.1.6.3.1 Product launches & enhancements 345 18.1.6.3.2 Deals 346 18.1.7 CHEMICAL COMPUTING GROUP ULC 347 18.1.7.1 Business overview 347 18.1.7.2 Products & services offered 348 18.1.7.3 Recent developments 348 18.1.7.3.1 Product launches & enhancements 348 18.1.7.3.2 Other developments 349 18.1.8 PHYSIOMICS PLC 350 18.1.8.1 Business overview 350 18.1.8.2 Products & services offered 351 18.1.8.3 Recent developments 352 18.1.8.3.1 Product launches & enhancements 352 18.1.8.3.2 Other developments 353 18.1.9 INSILICO MEDICINE 354 18.1.9.1 Business overview 354 18.1.9.2 Products & services offered 355 18.1.9.3 Recent developments 356 18.1.9.3.1 Product launches & enhancements 356 18.1.9.3.2 Deals 357 18.1.10 ROSA & CO. LLC 358 18.1.10.1 Business overview 358 18.1.10.2 Products & services offered 358 18.1.10.3 Recent developments 359 18.1.10.3.1 Deals 359 18.1.11 AITIA 360 18.1.11.1 Business overview 360 18.1.11.2 Products & services offered 361 18.1.11.3 Recent developments 361 18.1.11.3.1 Deals 361 18.1.12 INSTEM PLC 362 18.1.12.1 Business overview 362 18.1.12.2 Products & services offered 362 18.1.12.3 Recent developments 363 18.1.12.3.1 Product enhancements 363 18.1.12.3.2 Deals 363 18.1.13 ALLUCENT 364 18.1.13.1 Business overview 364 18.1.13.2 Products & services offered 364 18.1.13.3 Recent developments 365 18.1.13.3.1 Deals 365 18.1.13.3.2 Other developments 365 18.1.14 OPENEYE, CADENCE MOLECULAR SCIENCES 366 18.1.14.1 Business overview 366 18.1.14.2 Products & services offered 367 18.1.14.3 Recent developments 368 18.1.14.3.1 Product enhancements 368 18.1.14.3.2 Deals 369 18.1.14.3.3 Expansions 369 18.1.15 THE MATHWORKS, INC. 370 18.1.15.1 Business overview 370 18.1.15.2 Products & services offered 371 18.1.15.3 Recent developments 371 18.1.15.3.1 Product enhancements 371 18.1.16 VERISIM LIFE 372 18.1.16.1 Business overview 372 18.1.16.2 Products & services offered 372 18.1.16.3 Recent developments 373 18.1.16.3.1 Product launches & enhancements 373 18.1.16.3.2 Deals 373 18.1.16.3.3 Other developments 374 18.1.17 NETABOLICS 375 18.1.17.1 Business overview 375 18.1.17.2 Products & services offered 375 18.1.18 CHARNWOOD DISCOVERY 376 18.1.18.1 Business overview 376 18.1.18.2 Products & services offered 377 18.1.18.3 Recent developments 377 18.1.18.3.1 Deals 377 18.1.19 CELLWORKS GROUP, INC. 378 18.1.19.1 Business overview 378 18.1.19.2 Products & services offered 379 18.1.19.3 Recent developments 379 18.1.19.3.1 Product launches & enhancements 379 18.1.19.3.2 Other developments 380 18.1.20 IN SILICO BIOSCIENCES 381 18.1.20.1 Business overview 381 18.1.20.2 Products & services offered 382 18.2 OTHER PLAYERS 383 18.2.1 NOVA 383 18.2.2 INSITRO 384 18.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS 385 18.2.4 BIOSYMETRICS, INC. 385 18.2.5 METRUM RESEARCH GROUP 386 19 RESEARCH METHODOLOGY 387 19.1 RESEARCH APPROACH 387 19.1.1 SECONDARY RESEARCH 388 19.1.1.1 Key data from secondary sources 389 19.1.2 PRIMARY RESEARCH 389 19.1.2.1 Primary sources 390 19.1.2.2 Key data from primary sources 391 19.1.2.3 Breakdown of primaries 391 19.1.2.4 Insights from primary experts 392 19.2 RESEARCH METHODOLOGY 392 19.3 MARKET SIZE ESTIMATION 394 19.4 MARKET BREAKDOWN DATA TRIANGULATION 399 19.5 MARKET SHARE ESTIMATION 400 19.6 STUDY ASSUMPTIONS 400 19.7 RESEARCH LIMITATIONS 401 19.7.1 METHODOLOGY-RELATED LIMITATIONS 401 19.8 RISK ASSESSMENT 401 20 APPENDIX 402 20.1 DISCUSSION GUIDE 402 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 408 20.3 CUSTOMIZATION OPTIONS 410 20.4 RELATED REPORTS 410 20.5 AUTHOR DETAILS 411
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 38 TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 61 TABLE 3 BIOSIMULATION MARKET: ROLE IN ECOSYSTEM 66 TABLE 4 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY OFFERING (2025) 67 TABLE 5 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY REGION (2025) 68 TABLE 6 CASE 1: MODEL-INFORMED DEVELOPMENT FOR SLEEPING SICKNESS TREATMENT 71 TABLE 7 CASE 2: PBPK MODELING TO SUPPORT WIDER DISSOLUTION SPECIFICATIONS WITHOUT ADDITIONAL CLINICAL TRIALS 72 TABLE 8 CASE 3: COMPUTATIONAL MODELING TO ADVANCE AN ONCOLOGY DEVELOPMENT CANDIDATE 73 TABLE 9 US ADJUSTED RECIPROCAL TARIFF RATES 74 TABLE 10 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR BIOSIMULATION MARKET 81 TABLE 11 BIOSIMULATION MARKET: KEY PATENTS 83 TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 17 REGULATORY SCENARIO OF NORTH AMERICA 94 TABLE 18 REGULATORY SCENARIO OF EUROPE 94 TABLE 19 REGULATORY SCENARIO OF ASIA PACIFIC 95 TABLE 20 REGULATORY SCENARIO OF LATIN AMERICA 95 TABLE 21 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 96 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 99 TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 100 TABLE 24 UNMET NEEDS IN BIOSIMULATION MARKET 102 TABLE 25 END-USER EXPECTATIONS IN BIOSIMULATION MARKET 103 TABLE 26 BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 105 TABLE 27 BIOSIMULATION MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 28 BIOSIMULATION MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 107 TABLE 29 BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 30 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 31 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 32 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 33 BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 113 TABLE 34 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 114 TABLE 35 BIOSIMULATION MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 36 BIOSIMULATION MARKET FOR EARLY CLINICAL DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 37 BIOSIMULATION MARKET FOR LATE CLINICAL DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 38 BIOSIMULATION MARKET FOR REGULATORY, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 39 BIOSIMULATION MARKET FOR COMMERCIAL & MARKET ACCESS, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 40 BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 121 TABLE 41 BIOSIMULATION MARKET FOR ANTIBODY DESIGN, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 42 BIOSIMULATION MARKET FOR PEPTIDE DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 43 BIOSIMULATION MARKET FOR ENZYME ENGINEERING, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 44 BIOSIMULATION MARKET FOR BIFUNCTIONAL DEGRADERS, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 45 BIOSIMULATION MARKET FOR TCR MODELING, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 46 BIOSIMULATION MARKET FOR OTHER MODALITIES, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 47 BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 129 TABLE 48 BIOSIMULATION MARKET FOR MOLECULAR DESIGN & OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 49 BIOSIMULATION MARKET FOR PK/PD MODELING, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 50 BIOSIMULATION MARKET FOR PBPK MODELING, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 51 BIOSIMULATION MARKET FOR QUANTITATIVE SYSTEMS PHARMACOLOGY, BY REGION 2024–2031 (USD MILLION) 133 TABLE 52 BIOSIMULATION MARKET FOR ADME/TOXICITY PREDICTION, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 53 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 54 BIOSIMULATION MARKET FOR DISEASE MODELING, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 55 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 56 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 140 TABLE 57 BIOSIMULATION MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 58 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 59 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 60 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 61 BIOSIMULATION MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 63 BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 148 TABLE 64 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 65 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 66 BIOSIMULATION MARKET FOR HYBRID MODELS, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 67 BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 153 TABLE 68 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 69 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 70 BIOSIMULATION MARKET FOR CONSULTING SERVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 71 REGULATORY BODIES MARKET FOR REGULATORY BODIES, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 72 BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 73 BIOSIMULATION MARKET, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 74 NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 75 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 162 TABLE 76 NORTH AMERICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 162 TABLE 77 NORTH AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 163 TABLE 78 NORTH AMERICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 163 TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 164 TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 164 TABLE 81 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 165 TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 165 TABLE 83 US: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 166 TABLE 84 US: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 166 TABLE 85 US: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 167 TABLE 86 US: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 167 TABLE 87 US: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 168 TABLE 88 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 168 TABLE 89 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 169 TABLE 90 US: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 169 TABLE 91 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 170 TABLE 92 CANADA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 171 TABLE 93 CANADA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 171 TABLE 94 CANADA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 172 TABLE 95 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 172 TABLE 96 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 173 TABLE 97 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 173 TABLE 98 CANADA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 174 TABLE 99 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 100 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 176 TABLE 101 EUROPE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 176 TABLE 102 EUROPE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 177 TABLE 103 EUROPE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 177 TABLE 104 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 178 TABLE 105 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 178 TABLE 106 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 179 TABLE 107 EUROPE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 108 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 180 TABLE 109 GERMANY: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 180 TABLE 110 GERMANY: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 181 TABLE 111 GERMANY: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 181 TABLE 112 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182 TABLE 113 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 182 TABLE 114 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 183 TABLE 115 GERMANY: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 183 TABLE 116 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 184 TABLE 117 FRANCE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 184 TABLE 118 FRANCE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 185 TABLE 119 FRANCE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 185 TABLE 120 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186 TABLE 121 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 186 TABLE 122 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 187 TABLE 123 FRANCE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 124 UK: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 188 TABLE 125 UK: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 188 TABLE 126 UK: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 189 TABLE 127 UK: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 189 TABLE 128 UK: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 190 TABLE 129 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 190 TABLE 130 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 191 TABLE 131 UK: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 191 TABLE 132 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 192 TABLE 133 ITALY: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 192 TABLE 134 ITALY: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 193 TABLE 135 ITALY: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 193 TABLE 136 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194 TABLE 137 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 194 TABLE 138 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 195 TABLE 139 ITALY: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 140 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196 TABLE 141 SPAIN: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 196 TABLE 142 SPAIN: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 197 TABLE 143 SPAIN: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 197 TABLE 144 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198 TABLE 145 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 198 TABLE 146 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 199 TABLE 147 SPAIN: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 148 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 200 TABLE 149 REST OF EUROPE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 201 TABLE 150 REST OF EUROPE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 201 TABLE 151 REST OF EUROPE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 202 TABLE 152 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202 TABLE 153 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 203 TABLE 154 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 203 TABLE 155 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 204 TABLE 156 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 157 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207 TABLE 158 ASIA PACIFIC: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 207 TABLE 159 ASIA PACIFIC: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 208 TABLE 160 ASIA PACIFIC: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 208 TABLE 161 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 209 TABLE 162 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 209 TABLE 163 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 210 TABLE 164 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 165 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 211 TABLE 166 CHINA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 212 TABLE 167 CHINA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 212 TABLE 168 CHINA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 213 TABLE 169 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213 TABLE 170 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 214 TABLE 171 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 214 TABLE 172 CHINA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 215 TABLE 173 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216 TABLE 174 JAPAN: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 216 TABLE 175 JAPAN: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 217 TABLE 176 JAPAN: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 217 TABLE 177 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 178 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 218 TABLE 179 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 219 TABLE 180 JAPAN: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 181 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 220 TABLE 182 INDIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 220 TABLE 183 INDIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 221 TABLE 184 INDIA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 221 TABLE 185 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222 TABLE 186 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 222 TABLE 187 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 223 TABLE 188 INDIA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 223 TABLE 189 AUSTRALIA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 224 TABLE 190 AUSTRALIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 224 TABLE 191 AUSTRALIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 225 TABLE 192 AUSTRALIA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 225 TABLE 193 AUSTRALIA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 226 TABLE 194 AUSTRALIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 226 TABLE 195 AUSTRALIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 227 TABLE 196 AUSTRALIA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 197 SOUTH KOREA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 228 TABLE 198 SOUTH KOREA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 228 TABLE 199 SOUTH KOREA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 229 TABLE 200 SOUTH KOREA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 229 TABLE 201 SOUTH KOREA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 230 TABLE 202 SOUTH KOREA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 230 TABLE 203 SOUTH KOREA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 231 TABLE 204 SOUTH KOREA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 205 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 232 TABLE 206 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 232 TABLE 207 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 233 TABLE 208 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 233 TABLE 209 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 234 TABLE 210 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 234 TABLE 211 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 235 TABLE 212 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 235 TABLE 213 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 214 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 237 TABLE 215 LATIN AMERICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 237 TABLE 216 LATIN AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 238 TABLE 217 LATIN AMERICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 238 TABLE 218 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239 TABLE 219 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 239 TABLE 220 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 240 TABLE 221 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 240 TABLE 222 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 241 TABLE 223 BRAZIL: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 241 TABLE 224 BRAZIL: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 242 TABLE 225 BRAZIL: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 242 TABLE 226 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243 TABLE 227 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 243 TABLE 228 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 244 TABLE 229 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 244 TABLE 230 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 245 TABLE 231 MEXICO: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 245 TABLE 232 MEXICO: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 246 TABLE 233 MEXICO: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 246 TABLE 234 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 247 TABLE 235 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 247 TABLE 236 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 248 TABLE 237 MEXICO: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 238 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 249 TABLE 239 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 249 TABLE 240 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 250 TABLE 241 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 250 TABLE 242 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 251 TABLE 243 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 251 TABLE 244 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 252 TABLE 245 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 246 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 247 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 254 TABLE 248 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 254 TABLE 249 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 255 TABLE 250 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 255 TABLE 251 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256 TABLE 252 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 256 TABLE 253 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 257 TABLE 254 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 255 GCC COUNTRIES: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 256 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 258 TABLE 257 GCC COUNTRIES: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 259 TABLE 258 GCC COUNTRIES: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 259 TABLE 259 GCC COUNTRIES: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 260 TABLE 260 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260 TABLE 261 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 261 TABLE 262 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 261 TABLE 263 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 262 TABLE 264 SAUDI ARABIA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 263 TABLE 265 SAUDI ARABIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 263 TABLE 266 SAUDI ARABIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 264 TABLE 267 SAUDI ARABIA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 264 TABLE 268 SAUDI ARABIA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 265 TABLE 269 SAUDI ARABIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 265 TABLE 270 SAUDI ARABIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 266 TABLE 271 SAUDI ARABIA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 272 UAE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 267 TABLE 273 UAE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 267 TABLE 274 UAE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 268 TABLE 275 UAE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 268 TABLE 276 UAE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 269 TABLE 277 UAE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 269 TABLE 278 UAE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 270 TABLE 279 UAE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 270 TABLE 280 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 271 TABLE 281 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 271 TABLE 282 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 272 TABLE 283 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 272 TABLE 284 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 273 TABLE 285 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 273 TABLE 286 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 274 TABLE 287 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 288 SOUTH AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 275 TABLE 289 SOUTH AFRICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 275 TABLE 290 SOUTH AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 276 TABLE 291 SOUTH AFRICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 276 TABLE 292 SOUTH AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277 TABLE 293 SOUTH AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 277 TABLE 294 SOUTH AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 278 TABLE 295 SOUTH AFRICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 296 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 279 TABLE 297 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 279 TABLE 298 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 280 TABLE 299 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 280 TABLE 300 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281 TABLE 301 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 281 TABLE 302 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 282 TABLE 303 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 282 TABLE 304 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET, JANUARY 2023– JUNE 2026 283 TABLE 305 BIOSIMULATION MARKET: DEGREE OF COMPETITION 287 TABLE 306 BIOSIMULATION MARKET: REGION FOOTPRINT (20 COMPANIES) 294 TABLE 307 BIOSIMULATION MARKET: OFFERING FOOTPRINT (20 COMPANIES) 295 TABLE 308 BIOSIMULATION MARKET: PHASE OF DEVELOPMENT FOOTPRINT (20 COMPANIES) 296 TABLE 309 BIOSIMULATION MARKET: MODALITY FOOTPRINT (20 COMPANIES) 297 TABLE 310 BIOSIMULATION MARKET: END USER FOOTPRINT (20 COMPANIES) 298 TABLE 311 BIOSIMULATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 301 TABLE 312 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 302 TABLE 313 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY COMPONENT 302 TABLE 314 BIOSIMULATION MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 303 TABLE 315 BIOSIMULATION MARKET: DEALS, JANUARY 2023–JUNE 2026 304 TABLE 316 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 305 TABLE 317 CERTARA: COMPANY OVERVIEW 306 TABLE 318 CERTARA: PRODUCTS & SERVICES OFFERED 308 TABLE 319 CERTARA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 310 TABLE 320 CERTARA: DEALS, JANUARY 2023−JUNE 2026 313 TABLE 321 CERTARA: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 314 TABLE 322 DASSAULT SYSTÈMES: COMPANY OVERVIEW 316 TABLE 323 DASSAULT SYSTÈMES: PRODUCTS & SERVICES OFFERED 318 TABLE 324 DASSAULT SYSTÈMES: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023− JUNE 2026 319 TABLE 325 DASSAULT SYSTÈMES: DEALS, JANUARY 2023− JUNE 2026 321 TABLE 326 DASSAULT SYSTÈMES: OTHER DEVELOPMENTS, JANUARY 2023− JUNE 2026 322 TABLE 327 SCHRÖDINGER, INC.: COMPANY OVERVIEW 323 TABLE 328 SCHRÖDINGER, INC.: PRODUCTS & SERVICES OFFERED 325 TABLE 329 SCHRÖDINGER, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023− JUNE 2026 326 TABLE 330 SCHRÖDINGER, INC.: DEALS, JANUARY 2023−JUNE 2026 327 TABLE 331 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023− JUNE 2026 328 TABLE 332 SIMULATIONS PLUS: COMPANY OVERVIEW 330 TABLE 333 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED 332 TABLE 334 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 335 TABLE 335 SIMULATIONS PLUS: DEALS, JANUARY 2023−JUNE 2026 336 TABLE 336 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 338 TABLE 337 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW 340 TABLE 338 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED 342 TABLE 339 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 342 TABLE 340 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2023−JUNE 2026 343 TABLE 341 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW 344 TABLE 342 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED 345 TABLE 343 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 345 TABLE 344 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2023−JUNE 2026 346 TABLE 345 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW 347 TABLE 346 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED 348 TABLE 347 CHEMICAL COMPUTING GROUP ULC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 348 TABLE 348 CHEMICAL COMPUTING GROUP ULC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 349 TABLE 349 PHYSIOMICS PLC: COMPANY OVERVIEW 350 TABLE 350 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED 351 TABLE 351 PHYSIOMICS PLC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025 352 TABLE 352 PHYSIOMICS PLC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 353 TABLE 353 INSILICO MEDICINE: COMPANY OVERVIEW 354 TABLE 354 INSILICO MEDICINE: PRODUCTS & SERVICES OFFERED 355 TABLE 355 INSILICO MEDICINE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 356 TABLE 356 INSILICO MEDICINE: DEALS, JANUARY 2023−JUNE 2026 357 TABLE 357 ROSA & CO. LLC: COMPANY OVERVIEW 358 TABLE 358 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED 358 TABLE 359 ROSA & CO. LLC: DEALS, JANUARY 2023−JUNE 2026 359 TABLE 360 AITIA: COMPANY OVERVIEW 360 TABLE 361 AITIA: PRODUCTS & SERVICES OFFERED 361 TABLE 362 AITIA: DEALS, JANUARY 2023−JUNE 2026 361 TABLE 363 INSTEM PLC: COMPANY OVERVIEW 362 TABLE 364 INSTEM PLC: PRODUCTS & SERVICES OFFERED 362 TABLE 365 INSTEM PLC: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 363 TABLE 366 INSTEM PLC: DEALS, JANUARY 2023−JUNE 2026 363 TABLE 367 ALLUCENT: COMPANY OVERVIEW 364 TABLE 368 ALLUCENT: PRODUCTS & SERVICES OFFERED 364 TABLE 369 ALLUCENT: DEALS, JANUARY 2023−JUNE 2026 365 TABLE 370 ALLUCENT: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 365 TABLE 371 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW 366 TABLE 372 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED 367 TABLE 373 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 368 TABLE 374 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2023−JUNE 2026 369 TABLE 375 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS, JANUARY 2023−JUNE 2026 369 TABLE 376 THE MATHWORKS, INC.: COMPANY OVERVIEW 370 TABLE 377 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED 371 TABLE 378 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 371 TABLE 379 VERISIM LIFE: COMPANY OVERVIEW 372 TABLE 380 VERISIM LIFE: PRODUCTS & SERVICES OFFERED 372 TABLE 381 VERISIM LIFE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 373 TABLE 382 VERISIM LIFE: DEALS, JANUARY 2023−JUNE 2026 373 TABLE 383 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 374 TABLE 384 NETABOLICS: COMPANY OVERVIEW 375 TABLE 385 NETABOLICS: PRODUCTS & SERVICES OFFERED 375 TABLE 386 CHARNWOOD DISCOVERY: COMPANY OVERVIEW 376 TABLE 387 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED 377 TABLE 388 CHARNWOOD DISCOVERY: DEALS, JANUARY 2023−JUNE 2026 377 TABLE 389 CELLWORKS GROUP, INC.: COMPANY OVERVIEW 378 TABLE 390 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED 379 TABLE 391 CELLWORKS GROUP, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 379 TABLE 392 CELLWORKS GROUP, INC.: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 380 TABLE 393 IN SILICO BIOSCIENCES: COMPANY OVERVIEW 381 TABLE 394 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED 382 TABLE 395 RISK ASSESSMENT: BIOSIMULATION MARKET 401 FIGURE 1 BIOSIMULATION MARKET SEGMENTATION 35 FIGURE 2 MARKET SCENARIO 42 FIGURE 3 GLOBAL BIOSIMULATION MARKET, 2024–2031 42 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET, 2023–2026 43 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF BIOSIMULATION MARKET 44 FIGURE 6 HIGH-GROWTH SEGMENTS IN BIOSIMULATION MARKET, 2026–2031 45 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOSIMULATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46 FIGURE 8 INCREASING R&D INVESTMENTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE GROWTH IN BIOSIMULATION MARKET 48 FIGURE 9 SOFTWARE IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 49 FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50 FIGURE 11 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52 FIGURE 12 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 60 FIGURE 13 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS 64 FIGURE 14 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS 66 FIGURE 15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70 FIGURE 17 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015–2026 81 FIGURE 18 JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOSIMULATION MARKET 81 FIGURE 19 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR BIOSIMULATION MARKET (JANUARY 2015 TO JUNE 2026) 82 FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON BIOSIMULATION ACROSS INDUSTRIES 85 FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 87 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 99 FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 100 FIGURE 24 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT 161 FIGURE 25 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT 206 FIGURE 26 BIOSIMULATION MARKET: REVENUE ANALYSIS OF KEY PLAYERS 286 FIGURE 27 BIOSIMULATION MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 287 FIGURE 28 BIOSIMULATION MARKET: BRAND COMPARATIVE ANALYSIS 289 FIGURE 29 EV/EBITDA OF KEY VENDORS 290 FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 290 FIGURE 31 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS (2025) 292 FIGURE 32 BIOSIMULATION MARKET: COMPANY FOOTPRINT 293 FIGURE 33 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 300 FIGURE 34 CERTARA: COMPANY SNAPSHOT (2025) 307 FIGURE 35 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2025) 317 FIGURE 36 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2025) 324 FIGURE 37 SIMULATIONS PLUS: COMPANY SNAPSHOT (2025) 331 FIGURE 38 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2025) 341 FIGURE 39 PHYSIOMICS PLC: COMPANY SNAPSHOT (2025) 351 FIGURE 40 INSILICO MEDICINE: COMPANY SNAPSHOT (2025) 355 FIGURE 41 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2025) 367 FIGURE 42 RESEARCH DESIGN 387 FIGURE 43 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 391 FIGURE 44 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 393 FIGURE 45 BOTTOM-UP APPROACH 394 FIGURE 46 TOP-DOWN APPROACH 395 FIGURE 47 CAGR PROJECTIONS FROM ANALYSIS OF DROC IN BIOSIMULATION MARKET 396 FIGURE 48 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 396 FIGURE 49 DATA TRIANGULATION METHODOLOGY 399

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們